AU2001275346A1 - Compositions, kits, and methods for identification and modulation of type i diabetes - Google Patents

Compositions, kits, and methods for identification and modulation of type i diabetes

Info

Publication number
AU2001275346A1
AU2001275346A1 AU2001275346A AU7534601A AU2001275346A1 AU 2001275346 A1 AU2001275346 A1 AU 2001275346A1 AU 2001275346 A AU2001275346 A AU 2001275346A AU 7534601 A AU7534601 A AU 7534601A AU 2001275346 A1 AU2001275346 A1 AU 2001275346A1
Authority
AU
Australia
Prior art keywords
diabetes
type
kits
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275346A
Inventor
Michael C. Byrne
Andrew A. Hill
S. Brian Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Genetics Institute LLC
Original Assignee
General Hospital Corp
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Genetics Institute LLC filed Critical General Hospital Corp
Priority claimed from PCT/US2001/018418 external-priority patent/WO2001094636A1/en
Publication of AU2001275346A1 publication Critical patent/AU2001275346A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating type I diabetes. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of type I diabetes.
AU2001275346A 2000-06-05 2001-06-05 Compositions, kits, and methods for identification and modulation of type i diabetes Abandoned AU2001275346A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20970300P 2000-06-05 2000-06-05
US60/209703 2000-06-05
PCT/US2001/018418 WO2001094636A1 (en) 2000-06-05 2001-06-05 Compositions, kits, and methods for identification and modulation of type i diabetes

Publications (1)

Publication Number Publication Date
AU2001275346A1 true AU2001275346A1 (en) 2001-12-17

Family

ID=22779905

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275346A Abandoned AU2001275346A1 (en) 2000-06-05 2001-06-05 Compositions, kits, and methods for identification and modulation of type i diabetes

Country Status (8)

Country Link
US (2) US20020039736A1 (en)
EP (1) EP1290227B1 (en)
JP (1) JP2004510411A (en)
AT (1) ATE439453T1 (en)
AU (1) AU2001275346A1 (en)
CA (1) CA2411473A1 (en)
DE (1) DE60139553D1 (en)
ES (1) ES2331407T3 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257932A1 (en) * 1997-02-28 2006-11-16 Yaron Ilan Treatment of Crohn's disease
WO2004046098A2 (en) * 2002-05-16 2004-06-03 Vanderbilt University Method for predicting autoimmune diseases
EP1538218A1 (en) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Method to diagnose or screen for inflammatory diseases
EP1538219A1 (en) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Method to diagnose or screen for type 1 diabetes mellitus
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
CN101326439A (en) * 2005-10-11 2008-12-17 特提斯生物科学公司 Diabetes-associated markers and methods of use thereof
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2009015472A1 (en) * 2007-07-30 2009-02-05 London Health Sciences Centre Research Inc. Methods to diagnose type 1 diabetes by measuring cytokine and/or chemokine expression profiles.
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
BR112013001752A2 (en) 2010-07-23 2016-05-31 Harvard College method of detecting disease or condition using phagocytic cells
EP2596353A4 (en) 2010-07-23 2014-01-15 Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
WO2012012694A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
BR112013001754A2 (en) 2010-07-23 2016-05-31 Harvard College method for detecting disease marks or conditions in body fluids
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP3693742B1 (en) 2014-09-11 2022-04-06 Harry Stylli Methods of detecting prostate cancer
CN116808063B (en) * 2023-07-05 2023-12-12 中国医学科学院北京协和医院 Marker for diabetes and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4209216A1 (en) * 1992-03-21 1993-09-23 Boehringer Mannheim Gmbh HUMAN T-CELL MARKER HT6
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
AU2087799A (en) * 1997-12-31 1999-07-19 Brigham And Women's Hospital Diagnostic and therapeutic methods based upon valpha24jalphaq t cells

Also Published As

Publication number Publication date
WO2001094636A2 (en) 2001-12-13
JP2004510411A (en) 2004-04-08
ATE439453T1 (en) 2009-08-15
WO2001094636A8 (en) 2002-01-10
EP1290227B1 (en) 2009-08-12
US20050164233A1 (en) 2005-07-28
ES2331407T3 (en) 2010-01-04
US20020039736A1 (en) 2002-04-04
EP1290227A1 (en) 2003-03-12
CA2411473A1 (en) 2001-12-13
DE60139553D1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2001086002A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
AU2001275346A1 (en) Compositions, kits, and methods for identification and modulation of type i diabetes
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2001053836A3 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2001060860A3 (en) Genes differentially expressed in human prostate cancer and their use
DE60141950D1 (en) NETWORKED COMPOSITION NOT INCLUDING MUSHROOMS AND METHODS OF USE THEREOF
AU8112101A (en) Non-imidazole aryloxypiperidines
ATE324417T1 (en) BIOADHESIVE COMPOSITION CONTAINING POLYPHENOLIC PROTEIN
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
ATE272059T1 (en) ORGANIC SALTS OF ISOLEUCYL THIAZOLIDINE AND PYRROLIDINE AND THEIR USE AS DIPEPTIDYLPEPTIDASE INHIBITORS
SV2002000343A (en) PHARMACEUTICAL COMPOSISIONS OF INHIBITORS OF GLUCOGENO FOSFORILASA REF. PC10882 / 20147 / BB
AU3738597A (en) Molecular model for vla-4 inhibitors
AU7585598A (en) Raf kinase inhibitors
MXPA04004347A (en) Novel difunctional photoinitiators.
WO2002044418A3 (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2004088943A3 (en) Identifying and using indentities of communication partners deemed to be known to a user
WO2001018542A3 (en) Identification, assessment, prevention, and therapy of ovarian cancer
WO2002044360A3 (en) Modified arginine deiminase
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
IL138688A0 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
DE60107457D1 (en) PRE-NETWORKING COMPOSITION
HK1020211A1 (en) Molecular model for vla-4 inhibitors vla-4
WO2004009843A3 (en) Detection of microorganisms